OncoMed Pharmaceuticals Inactive 10-Q2016 Q2 Quarterly report

Filed: 9 Aug 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abroad, alleging, antibody, appeal, appealing, aspect, assert, ATM, attempt, average, avoid, aware, brought, cease, challenge, challenging, claim, claimed, claiming, commonplace, construed, counter, country, court, decision, defendant, defending, delay, delayed, disrupt, enforce, EPO, Europe, European, expiration, expire, final, forced, formally, found, freedom, half, harm, holder, increasingly, infringe, infringed, infringement, infringing, instance, inter, interference, interpreted, invalid, invalidate, invalidated, invalidity, invention, jurisdiction, literature, misappropriate, misappropriation, narrow, narrowed, narrowing, narrowly, nonexclusive, opposed, opposition, patent, patented, pending, practice, presumption, prevent, prevented, priority, proceeding, put, question, reached, reexamination, refuse, review, revocation, revoked, signaling, stop, suit, terminated, thereunder, Trademark, ultimate, ultimately, unauthorized, unenforceability, unenforceable, unfavorable, unsuccessful, USPTO, violate, weaken, weighted, willfully

Removed: Abraxane, allocable, allocate, analyzed, apply, assuming, carried, collaborator, commencement, commensurate, component, comprehensive, considerable, consistent, Conversely, counterparty, customer, deliverable, delivered, determination, determining, element, enrolled, entirety, entity, estimating, evidence, exercised, exercising, gathering, gemcitabine, greater, identified, inception, incremental, intent, liquid, nonrefundable, objective, originally, passage, priced, proceed, prospective, regularly, retrospectively, selling, separate, separated, single, target, unit, Unrealized

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

OncoMed Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of OncoMed Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended June 30, 2016, as filed with the Securities and Exchange Commission (the “Report”), Paul J. Hastings, Chairman and Chief Executive Officer of the Company, and Sunil Patel, Senior Vice President and Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2016

/s/ Paul J. Hastings

Paul J. Hastings

Chairman and Chief Executive Officer

(principal executive officer)

/s/ Sunil Patel

Sunil Patel

Senior Vice President and Chief Financial Officer

(principal financial and accounting officer)

This certification is being furnished to accompany the Report pursuant to 18 U.S.C. § 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.